USPTO serial 98141705
BIVISION
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- PODESTA, GIDETTE
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with BIVISION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Bivision Pharmaceuticals(Nanjing),Inc.
Nanjing, CN
Other trademarks owned by Bivision Pharmaceuticals(Nanjing),Inc.
Bivision Pharmaceuticals(Nanjing),Inc.
Nanjing, CN
Other trademarks owned by Bivision Pharmaceuticals(Nanjing),Inc.
Bivision Pharmaceuticals(Shanghai),Inc.
Shanghai, CN
Other trademarks owned by Bivision Pharmaceuticals(Shanghai),Inc.
Bivision Pharmaceuticals(Shanghai),Inc.
Shanghai, CN
Other trademarks owned by Bivision Pharmaceuticals(Shanghai),Inc.
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic radiopharmaceutical agent for use in PET imaging; Diagnostic radiopharmaceutical preparations; Diagnostic reagents for medicinal use; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Pharmaceutical preparations for use in urology; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; Tumor suppressing agents | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Bivision Pharmaceuticals(Nanjing),Inc.
- Other trademarks owned by Bivision Pharmaceuticals(Nanjing),Inc.
- Other trademarks owned by Bivision Pharmaceuticals(Shanghai),Inc.
- Other trademarks owned by Bivision Pharmaceuticals(Shanghai),Inc.
- Other trademarks in Class 005
- Similar marks named BIVISION
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 2, 2025 | WOAG | WITHDRAWAL OF ATTORNEY GRANTED | — |
| Jun 2, 2025 | WOAR | TEAS WITHDRAWAL OF ATTORNEY RECEIVED | — |
| Mar 3, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 3, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 3, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 3, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 23, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 28, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 28, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 8, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 19, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 19, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 19, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 19, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 19, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 18, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 20, 2023 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Sep 19, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 25, 2023 | NWAP | NEW APPLICATION ENTERED | — |